Hypoglycaemia continuous subcutaneous insulin

Linkeschova R, Raoul M, Bott U, Berger M, Spraul M. Less severe hypoglycaemia, better metabolic control, and improved quality of life in type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med 2002 19(9) 746-51. 

Treatments using insulin analogues or insulin pump treatment with continuous subcutaneous insulin infusion (CSII) have less variability and a lower incidence of hypoglycaemia than seen with traditional insulins and delivery systems. 

Insuhn therapy may be required in the control of type II diabetes. InsuUn is given by subcutaneous injection, usually several times a day in an attempt to mimic the normal physiological variation. The most serious risk with insulin therapy is that of hypoglycaemia. Hypoglycaemia develops if insulin is injected and not followed by a meal and is a medical emergency. Fat hypertrophy may occur if insulin is continually injected into the same site. Rotation of the sites of injection is therefore advised (30c). 

---